Gestational diabetes: screening and postpartum follow-up
BioMG follows French guidelines. Adapt it to the guidelines and the tests available where you practise.
Screening during pregnancy (at-risk woman)
1st trimester (first antenatal visit)
- Fasting plasma glucose
Between 24 and 28 weeks of gestation (if 1st-trimester fasting plasma glucose < 0.92 g/L)
- 75 g OGTT with plasma glucose at 0, 1 and 2 hours (fasting, without prior diet)
Do not order
After gestational diabetes
Postnatal visit (6 to 8 weeks after delivery)
- Fasting plasma glucose
- 75 g OGTT (more sensitive than fasting plasma glucose)if neededScreening can be done by fasting plasma glucose or by OGTT; fasting plasma glucose is less sensitive than OGTT for the diagnosis of type 2 diabetes [3]. Higher risk of type 2 diabetes: overweight, diagnosis before 24 weeks, high glucose values on OGTT, insulin during pregnancy [3].
- Lipid profile (if other cardiovascular risk factors)if neededFollow-up after gestational diabetes includes regular screening for and treatment of other cardiovascular risk factors, including dyslipidaemia [3].
Then every 1 to 3 years, and before any new pregnancy
- Fasting plasma glucose (or 75 g OGTT)
Do not order
Sources (12)
- Cinelli H, Lelong N, Le Ray C et ENP2021 Study group. Rapport de l'Enquête nationale périnatale 2021 en France métropolitaine : les naissances, le suivi à 2 mois et les établissements. Situation et évolution depuis 2016. Inserm, octobre 2022 (mise à jour juin 2023).
- Wery E, Vambergue A, Le Goueff F, Vincent D, Deruelle P. Impact des nouveaux critères de dépistage sur la prévalence du diabète gestationnel. J Gynecol Obstet Biol Reprod (Paris). 2014;43(4):307-13.
- Collège national des gynécologues et obstétriciens français (CNGOF), Société francophone du diabète (SFD). Le diabète gestationnel. Recommandations pour la pratique clinique (texte court), décembre 2010. Texte long : J Gynecol Obstet Biol Reprod 2010;39(8 Suppl 2):S1-S342 ; résumé en anglais : Diabetes Metab. 2010;36(6 Pt 2):695-9.
- International Association of Diabetes and Pregnancy Study Groups Consensus Panel; Metzger BE, Gabbe SG, Persson B, et al. International Association of Diabetes and Pregnancy Study Groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care. 2010;33(3):676-82.
- US Preventive Services Task Force. Screening for Gestational Diabetes: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;326(6):531-538 (recommandation finale du 10 août 2021).
- Gemeinsamer Bundesausschuss (G-BA, Allemagne). Mutterschafts-Richtlinie, version du 21 septembre 2023, dernière modification du 16 juillet 2026, en vigueur depuis le 25 août 2026.
- Sweeting A, Hare MJL, Jersey SJ, Shub AL, Zinga J, Foged C, Hall RM, Wong T, Simmons D. Australasian Diabetes in Pregnancy Society (ADIPS) 2025 consensus recommendations for the screening, diagnosis and classification of gestational diabetes. Med J Aust. 2025;223(3):161-167.
- National Institute for Health and Care Excellence. Diabetes in pregnancy: management from preconception to the postnatal period. NICE guideline NG3, 25 février 2015, actualisée le 16 décembre 2020.
- National Institute for Health and Care Excellence, National Collaborating Centre for Women's and Children's Health. Diabetes in pregnancy: methods, evidence and recommendations (guide complet de NG3), 2015.
- Will JS, Crellin H. Gestational Diabetes Mellitus: Update on Screening, Diagnosis, and Management. Am Fam Physician. 2023;108(3):249-258.
- Assurance maladie. Nomenclature des actes de biologie médicale (NABM), version 105 : acte 1577 (HbA1c).
- Collège national des gynécologues et obstétriciens français (CNGOF). Post-partum. Recommandations pour la pratique clinique, 2015 (texte court : Sénat MV, et al. J Gynecol Obstet Biol Reprod (Paris). 2015;44(10):1157-66).